The science behind new diabetes drugs underscores how far we've come from the days of purified pork insulin. Even so, most ads stick to traditional copy.
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
Sproutel CEO Aaron Horowitz talks about how Jerry the Bear came to life and why endocrinologists are stocking the bear in their offices.
A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs
Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.
Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.
The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus
The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.
Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.
The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma
Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing
The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.
The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.
The drugmakers worked with Evoke Health to develop a campaign that would differentiate the third-in-class type-2 diabetes drug in an increasingly competitive market.
Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic
The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study